Abstract
We studied aberrant changes (A-IgC) in the production of monoclonal intact immunoglobulin (M-Ig) or serum free light chains (sFLC) during symptomatic MM patients’ relapse and we evaluated their frequency and the associated disease characteristics.
Patients and Methods: 234 symptomatic MM patients, with available follow-up M-Ig and sFLC measurements, were retrospectively studied. Light chain escape (LCE) was defined as sFLC increase with stable or falling M-Ig, M-Ig escape (MCE) as decreasing sFLC with increasing M-Ig, de-differentiation (DD) as clinical relapse with normal or decreased MIg and sFLC and Clonal Domination (CD) as normalization of formerly increased IgG, IgA or FLC in relapsing patients presenting increase of another monoclonal component.
Results: A-IgC was observed in 18% of patients, LCE in 8%, MCE in 3%, DD in 2% and CD in 5%; The median time from diagnosis to A-IgC was 48.5, 35.5, 31 and 46 months for LCE, MCE, DD and CD respectively. Median survival from A-IgC to last follow-up or death was 2.6, 3.3 and 6.3 months respectively for LCE, MCE and DD versus 31.1 months for CD patients (p=0.0002).
Patients received a median of 3 treatment lines, including novel agents and/or ASCT, prior to A-IgC. In conclusion, LCE, MCE and DD are late events in the course of MM, observed in heavily pre-treated patients, associated with a very aggressive disease with shortened survival thereafter, probably due to the emergence of new resistant clones or to the dominance of pre-existing minor ones.
Keywords: Anatomical site, clonality, composite lymphomas, hodgkin lymphoma, molecular techniques, morphology, non Hodgkin Lymphoma.
Current Cancer Therapy Reviews
Title:Aberrant Immunoglobulin Variations as Indicators of Eventual Clonal Changes in Symptomatic Multiple Myeloma Patients' Course
Volume: 10 Issue: 2
Author(s): Aikaterini Bitsani, Marie-Christine Kyrtsonis, Panayiotis Panayiotidis, Nikolitsa Kafasi, Kalliroi Tsalimalma, Panagiotis Tsaftaridis, Maria M. Angelopoulou, Theodoros P. Vassilakopoulos, Maria Dimou, Tatiana Tzenou, Vasiliki Bartzis, Eftychia Nikolaou, Anna Efthymiou, Ilias Pessach, Vasiliki Karali, Ioanna Vardounioti, Nora-Athina Vyniou, Theodoros Iliakis, Aikaterini Sarris, Dimitrios Maltezas and Efstathios Koulieris
Affiliation:
Keywords: Anatomical site, clonality, composite lymphomas, hodgkin lymphoma, molecular techniques, morphology, non Hodgkin Lymphoma.
Abstract: We studied aberrant changes (A-IgC) in the production of monoclonal intact immunoglobulin (M-Ig) or serum free light chains (sFLC) during symptomatic MM patients’ relapse and we evaluated their frequency and the associated disease characteristics.
Patients and Methods: 234 symptomatic MM patients, with available follow-up M-Ig and sFLC measurements, were retrospectively studied. Light chain escape (LCE) was defined as sFLC increase with stable or falling M-Ig, M-Ig escape (MCE) as decreasing sFLC with increasing M-Ig, de-differentiation (DD) as clinical relapse with normal or decreased MIg and sFLC and Clonal Domination (CD) as normalization of formerly increased IgG, IgA or FLC in relapsing patients presenting increase of another monoclonal component.
Results: A-IgC was observed in 18% of patients, LCE in 8%, MCE in 3%, DD in 2% and CD in 5%; The median time from diagnosis to A-IgC was 48.5, 35.5, 31 and 46 months for LCE, MCE, DD and CD respectively. Median survival from A-IgC to last follow-up or death was 2.6, 3.3 and 6.3 months respectively for LCE, MCE and DD versus 31.1 months for CD patients (p=0.0002).
Patients received a median of 3 treatment lines, including novel agents and/or ASCT, prior to A-IgC. In conclusion, LCE, MCE and DD are late events in the course of MM, observed in heavily pre-treated patients, associated with a very aggressive disease with shortened survival thereafter, probably due to the emergence of new resistant clones or to the dominance of pre-existing minor ones.
Export Options
About this article
Cite this article as:
Bitsani Aikaterini, Kyrtsonis Marie-Christine, Panayiotidis Panayiotis, Kafasi Nikolitsa, Tsalimalma Kalliroi, Tsaftaridis Panagiotis, Angelopoulou M. Maria, Vassilakopoulos P. Theodoros, Dimou Maria, Tzenou Tatiana, Bartzis Vasiliki, Nikolaou Eftychia, Efthymiou Anna, Pessach Ilias, Karali Vasiliki, Vardounioti Ioanna, Vyniou Nora-Athina, Iliakis Theodoros, Sarris Aikaterini, Maltezas Dimitrios and Koulieris Efstathios, Aberrant Immunoglobulin Variations as Indicators of Eventual Clonal Changes in Symptomatic Multiple Myeloma Patients' Course, Current Cancer Therapy Reviews 2014; 10 (2) . https://dx.doi.org/10.2174/157339471002141124122344
DOI https://dx.doi.org/10.2174/157339471002141124122344 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Potential Beneficial Effects of Garlic in Oncohematology
Mini-Reviews in Medicinal Chemistry (Review Article) Screening for Disease-Markers and Investigating Drug Effects by Proteome Profiling: Can it Meet Expectations?
Combinatorial Chemistry & High Throughput Screening Adenosine Deaminase in the Modulation of Immune System and its Potential as a Novel Target for Treatment of Inflammatory Disorders
Current Drug Targets Agonists and Antagonists Acting at P2X7 Receptor
Current Topics in Medicinal Chemistry MicroRNA Regulation of Programmed Cell Death Pathways in Cancer
Current Chemical Biology Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy Chemical Metabolic Inhibitors for the Treatment of Blood-Borne Cancers
Anti-Cancer Agents in Medicinal Chemistry Pharmacogenomics of Non-Small Cell Lung Cancer
Current Pharmacogenomics Common and Uncommon Features of Rheumatoid Arthritis and Chronic Obstructive Pulmonary Disease: Clues to a Future Therapy
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Development of Radicicol Analogues
Current Cancer Drug Targets Therapeutical Potential of CB<sub>2</sub> Receptors in Immune-Related Diseases
Current Molecular Pharmacology Molecular Imaging of Apoptosis In Vivo with Scintigraphic and Optical Biomarkers – A Status Report
Anti-Cancer Agents in Medicinal Chemistry Anticancer Potential of Dietary Natural Products: A Comprehensive Review
Anti-Cancer Agents in Medicinal Chemistry Imatinib Mesylate (Gleevec©): Targeted Therapy Against Cancer with Immune Properties
Endocrine, Metabolic & Immune Disorders - Drug Targets Does Cyclic Dependent Kinase 5 Play a Significant Role in Determination of Stroke Outcome? Possible Therapeutic Implications
Central Nervous System Agents in Medicinal Chemistry In Silico Identification and Analysis of Drug Resistant Mutants of ABL Tyrosine Kinase Based on Detrimental Missense Mutations
Current Signal Transduction Therapy Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma
Current Cancer Drug Targets Are the Antioxidant Properties of Carvedilol Important for the Protection of Cardiac Mitochondria?
Current Vascular Pharmacology Drug-Lipid Membrane Interaction Mechanisms Revealed Through Molecular Simulations
Current Physical Chemistry Random Mutagenesis Methods for In Vitro Directed Enzyme Evolution
Current Protein & Peptide Science